Current developments in castration-resistant prostate cancer therapies

Current developments in castration-resistant prostate cancer therapies

VJOncology

3 years
358 Views
Share
Want to watch this again later?
Sign in to add this video to a playlist. Login
0 0
Category:
Description:
Neal Shore, MD of the Carolina Urologic Research Center, Myrtle Beach, SC, discusses the advances in the development of treatments and therapies for patients with advanced prostate cancer. Dr Shore highlights that patients who initially failed localized treatments and progressed to a requirement for androgen suppressive immunotherapy, will invariably convert from an androgen sensitive state to a castration-resistant state. Since 2010, five new therapeutics have been approved worldwide. However, there are still challenges surrounding accessibility and cost. According to Dr Shore, there is a paucity in terms of sequencing data and combination data that are done in a large, prospective manner. Investigators are now trying to understand the adverse event profiles of sequencing and combining, and ultimately the outcome analyses. He also mentions that currently, there are two taxane-based chemotherapies in castration-resistant prostate cancer: a unique radio pharmaceutical, an immunotherapeutic and two oral novel hormonal lines of therapy. According to Dr Shore, we may see more immunotherapies for castration-resistant prostate cancer in the foreseeable future. New therapeutics for bladder and urinal diseases are being introduced, which he considers to be extremely exciting lines of research. Additionally, new oral therapies such as DNA repair mechanism approaches or PARP inhibitors, are also being further developed, which now provides new hope for patients with prostate cancer. Recorded at the American Society of Oncology (ASCO) 2016 Annual Meeting held in Chicago, IL.
Up Next Autoplay
IASLC on Multidisciplinary Recommendations for Pathologic Assessment of Lung Cancer Resection
IASLC on Multidisciplinary Recommendations for Pathologic Assessment of Lung Cancer Resection
Category: Non-Small Cell Lung Cancer
9 Views
University of Torino 1 day
Oncopeptides to Highlight Data from Melflufen Clinical Program in Multiple Myeloma and AL Amyloidosis in Six Presentations at ASH Annual Meeting 2019
Oncopeptides to Highlight Data from Melflufen Clinical Program in Multiple Myeloma and AL Amyloidosis in Six Presentations at ASH Annual Meeting 2019
Category: News
19 Views
Cancer-News 1 day
Phase I/II Study of Ruxolitinib @SeattleCCA @heidigraydrezn5 @UWashOBGYN
Phase I/II Study of Ruxolitinib @SeattleCCA @heidigraydrezn5 @UWashOBGYN
Category: Ovarian Cancer
22 Views
SeattleCCA 6 days
CDX-1140 Shows Clinical and Biological Efficacy in Patients with Advanced Solid Tumors in Phase 1 Dose Escalation Studies
CDX-1140 Shows Clinical and Biological Efficacy in Patients with Advanced Solid Tumors in Phase 1 Dose Escalation Studies
Category: Immunotherapy
12 Views
Cancer-News 6 days
Immune and Circulating Tumor DNA Profiling #NSCLC @MDAndersonNews
Immune and Circulating Tumor DNA Profiling #NSCLC @MDAndersonNews
Category: Non-Small Cell Lung Cancer
9 Views
MD Anderson 6 days
KY1044 Targets ICOS @kymabltd @rcasainson
KY1044 Targets ICOS @kymabltd @rcasainson
Category: Other
3 Views
Cancer-News 6 days
What Mechanism of Action is the Most Relevant for Targeting ICOS? @rcasainson @KymabLtd
What Mechanism of Action is the Most Relevant for Targeting ICOS? @rcasainson @KymabLtd
Category: Other
7 Views
Cancer-News 6 days
DNA Profiling Following Radiation Treatment in #NSCLC @MDAndersonNews
DNA Profiling Following Radiation Treatment in #NSCLC @MDAndersonNews
Category: Non-Small Cell Lung Cancer
26 Views
MD Anderson 6 days
New Findings for KY1044 Anti-ICOS Program at the #CICON2019 Annual Meeting @kymabltd @rcasainson
New Findings for KY1044 Anti-ICOS Program at the #CICON2019 Annual Meeting @kymabltd @rcasainson
Category: Other
12 Views
Cancer-News 6 days
Ideal Management of Steroid Refractory in GVHD @OSUCCC_James
Ideal Management of Steroid Refractory in GVHD @OSUCCC_James
Category: News
10 Views
OSUCCC 1 week